[go: up one dir, main page]

WO1997009976A3 - Procede d'attenuation de troubles dus a des neurotoxines par des chelatants du zinc - Google Patents

Procede d'attenuation de troubles dus a des neurotoxines par des chelatants du zinc Download PDF

Info

Publication number
WO1997009976A3
WO1997009976A3 PCT/IB1996/000981 IB9600981W WO9709976A3 WO 1997009976 A3 WO1997009976 A3 WO 1997009976A3 IB 9600981 W IB9600981 W IB 9600981W WO 9709976 A3 WO9709976 A3 WO 9709976A3
Authority
WO
WIPO (PCT)
Prior art keywords
neurotoxic injury
zinc chelators
reducing neurotoxic
reducing
injury
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB1996/000981
Other languages
English (en)
Other versions
WO1997009976A2 (fr
Inventor
Dennis Wonkyu Choi
Jae-Young Koh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Washington
Washington University in St Louis WUSTL
Original Assignee
University of Washington
Washington University in St Louis WUSTL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Washington, Washington University in St Louis WUSTL filed Critical University of Washington
Priority to AU68879/96A priority Critical patent/AU6887996A/en
Publication of WO1997009976A2 publication Critical patent/WO1997009976A2/fr
Publication of WO1997009976A3 publication Critical patent/WO1997009976A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention porte sur des composés chélatants du zinc pharmaceutiquement acceptables, utilisés dans la fabrication de médicaments destinés au traitement de troubles dus à des neurotoxines.
PCT/IB1996/000981 1995-09-01 1996-08-23 Procede d'attenuation de troubles dus a des neurotoxines par des chelatants du zinc Ceased WO1997009976A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU68879/96A AU6887996A (en) 1995-09-01 1996-08-23 Method of reducing neurotoxic injury with zinc chelators

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US313495P 1995-09-01 1995-09-01
US60/003,134 1995-09-01
US735695P 1995-11-20 1995-11-20
US60/007,356 1995-11-20

Publications (2)

Publication Number Publication Date
WO1997009976A2 WO1997009976A2 (fr) 1997-03-20
WO1997009976A3 true WO1997009976A3 (fr) 1997-05-22

Family

ID=26671370

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB1996/000981 Ceased WO1997009976A2 (fr) 1995-09-01 1996-08-23 Procede d'attenuation de troubles dus a des neurotoxines par des chelatants du zinc

Country Status (2)

Country Link
AU (1) AU6887996A (fr)
WO (1) WO1997009976A2 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7244764B2 (en) 2003-06-23 2007-07-17 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
US7414076B2 (en) 2003-06-23 2008-08-19 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
US8835654B2 (en) 2004-12-22 2014-09-16 Bhi Limited Partnership Method and compositions for treating amyloid-related diseases

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5834457A (en) * 1996-01-26 1998-11-10 The Regents Of The University Of California Method of modulating radical formation by mutant cuznsod enzymes
US7045531B1 (en) 1997-03-11 2006-05-16 The General Hospital Corporation Composition comprising a metal chelator and a method of treating amyloidosis by administering the metal chelator
US6323218B1 (en) 1998-03-11 2001-11-27 The General Hospital Corporation Agents for use in the treatment of Alzheimer's disease
US6638711B1 (en) 1999-04-29 2003-10-28 The General Hospital Corporation Methods for identifying an agent that inhibits oxygen-dependent hydrogen peroxide formation activity but does not inhibit superoxide-dependent hydrogen peroxide formation
US6562836B1 (en) * 1999-05-24 2003-05-13 Queen's University Of Kingston Methods and compounds for inhibiting amyloid deposits
US6407090B1 (en) 1999-06-23 2002-06-18 Zinc Therapeutics Canada, Inc. Zinc ionophores as anti-apoptotic agents
AU2002357096B2 (en) * 2001-12-06 2008-10-16 Fibrogen, Inc. Methods of increasing endogenous erythropoietin (EPO)
AU2002950217A0 (en) * 2002-07-16 2002-09-12 Prana Biotechnology Limited 8- Hydroxy Quinoline Derivatives
IL151921A0 (en) 2002-09-25 2003-04-10 Pharma Ltd D Liphopilic diesters of chelating agent for inhibition of enzyme activity
CA2520259A1 (fr) 2003-04-11 2004-10-28 Anormed Inc. Composes de liaison aux recepteurs de chimiokine cxcr4
KR101547612B1 (ko) 2006-10-12 2015-08-27 비에이치아이 리미티드 파트너쉽 3-아미노-1-프로판설폰산을 전달하기 위한 방법, 화합물, 조성물 및 비히클
US10369108B2 (en) 2013-03-15 2019-08-06 Mylan Laboratories, Inc. Hot melt granulation formulations of poorly water-soluble active agents
WO2016164685A1 (fr) * 2015-04-10 2016-10-13 Ohio University Compositions et méthodes destinées à des tissus traumatisés, comprenant des chélateurs du zinc
WO2016179217A1 (fr) * 2015-05-06 2016-11-10 Ohio University Chélation d'ions métalliques pour améliorer l'effet d'un activateur tissulaire du plasminogène (tpa) dans le cadre de la thrombolyse
ES2907489T3 (es) 2015-12-14 2022-04-25 X4 Pharmaceuticals Inc Métodos para el tratamiento del cáncer
US11357742B2 (en) 2015-12-14 2022-06-14 X4 Pharmaceuticals, Inc. Methods for treating cancer
SI3393468T1 (sl) 2015-12-22 2023-01-31 X4 Pharmaceuticals, Inc. Postopki za zdravljenje bolezni imunske pomanjkljivosti
WO2017177230A1 (fr) 2016-04-08 2017-10-12 X4 Pharmaceuticals, Inc. Méthodes de traitement du cancer
CA3027500A1 (fr) 2016-06-21 2017-12-28 X4 Pharmaceuticals, Inc. Inhibiteurs de cxcr4 et leurs utilisations
CA3027495A1 (fr) 2016-06-21 2017-12-28 X4 Pharmaceuticals, Inc. Inhibiteurs de cxcr4 et leurs utilisations
WO2017223239A1 (fr) 2016-06-21 2017-12-28 X4 Pharmaceuticals, Inc. Inhibiteurs de cxcr4 et leurs utilisations
US10548889B1 (en) 2018-08-31 2020-02-04 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use
WO2021183650A1 (fr) 2020-03-10 2021-09-16 X4 Pharmaceuticals, Inc. Méthodes de traitement de la neutropénie

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3932338A1 (de) * 1989-09-28 1991-04-11 Nmi Naturwissenschaftl U Mediz Verfahren zur praeventiven therapie von morbus alzheimer
US5206264A (en) * 1991-11-04 1993-04-27 Cypros Pharmaceutical Corporation Use of disulfiram to prevent cardiovascular damage
WO1993010459A1 (fr) * 1991-11-12 1993-05-27 The University Of Melbourne Procede de diagnostic et de traitement de la maladie d'alzheimer
EP0656362A1 (fr) * 1993-12-03 1995-06-07 Lilly Industries Limited Composés chimiques
WO1996006639A2 (fr) * 1994-09-01 1996-03-07 Medico Pharma Vertriebs Gmbh Nouveaux medicaments contenant des agents formant des chelates

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3932338A1 (de) * 1989-09-28 1991-04-11 Nmi Naturwissenschaftl U Mediz Verfahren zur praeventiven therapie von morbus alzheimer
US5206264A (en) * 1991-11-04 1993-04-27 Cypros Pharmaceutical Corporation Use of disulfiram to prevent cardiovascular damage
US5373021A (en) * 1991-11-04 1994-12-13 Cypros Pharmaceutical Corporation Use of disulfiram for Neuronal Protection
WO1993010459A1 (fr) * 1991-11-12 1993-05-27 The University Of Melbourne Procede de diagnostic et de traitement de la maladie d'alzheimer
EP0656362A1 (fr) * 1993-12-03 1995-06-07 Lilly Industries Limited Composés chimiques
WO1996006639A2 (fr) * 1994-09-01 1996-03-07 Medico Pharma Vertriebs Gmbh Nouveaux medicaments contenant des agents formant des chelates

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ARISPE ET AL: "zn2+ interaction with alzheimer amyloid beta protein calcium channels", P.N.A.S, vol. 93, no. 4, February 1996 (1996-02-01), pages 1710 - 1715, XP002028934 *
CUAJUNGCO ET AL: "prevention of zinc neurotoxicity in vivo by tpen", NEUROREPORT, vol. 7, no. 7, 17 May 1996 (1996-05-17), pages 1301 - 1304, XP000670010 *
DATABASE DISSERTATION ABSTRACTS umi; 1995, LEE P.J.: "modulation of central cholinergic excitotoxicity by zinc chelating agents", XP002028935 *
KOH ET AL: "the role of zinc in selective neuronal death after transient global cerebral ischemia", SCIENCE, vol. 272, no. 5264, 17 May 1996 (1996-05-17), pages 1013 - 1016, XP002028933 *
KOH ET AL: "zinc toxicity on cultured cortical neurons", NEUROSCIENCE, vol. 60, no. 4, 1994, pages 1049 - 1057, XP000670025 *
LEE P.J.: "idem", MASTERS ABSTRACTS, vol. 34, no. 04, 1995, pages 1564 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7244764B2 (en) 2003-06-23 2007-07-17 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
US7414076B2 (en) 2003-06-23 2008-08-19 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
US7598269B2 (en) 2003-06-23 2009-10-06 Bellus Health (International) Limited Methods and compositions for treating amyloid-related diseases
US8835654B2 (en) 2004-12-22 2014-09-16 Bhi Limited Partnership Method and compositions for treating amyloid-related diseases

Also Published As

Publication number Publication date
AU6887996A (en) 1997-04-01
WO1997009976A2 (fr) 1997-03-20

Similar Documents

Publication Publication Date Title
WO1997009976A3 (fr) Procede d&#39;attenuation de troubles dus a des neurotoxines par des chelatants du zinc
ZA951107B (en) Substituted spiro compounds for the treatment of inflammation
ZA961150B (en) Substituted isoxazoles for the treatment of inflammation.
CA2272584A1 (fr) Nouveaux derives de pyrazole substitues pour le traitement de maladies cardio-vasculaires
AU3201095A (en) Substituted thiazoles for the treatment of inflammation
CA2180535A1 (fr) Procede de traitement du psoriasis par omeprazole ou autres composes apparentes
EP1555025A3 (fr) Utilisation d&#39;analogues de déhydroépiandrostérone pour le traitement de l&#39;asthme
AU5860396A (en) Substituted oxazoles for the treatment of inflammation
AU2388895A (en) Substituted cyclopentadienyl compounds for the treatment of inflammation
AU2424895A (en) Substituted spirodienes for the treatment of inflammation
AU7310896A (en) Use of nitroflavonoids for the treatment of anxiety
AU3187595A (en) Compounds for the treatment of restenosis
AU2806692A (en) Medicament for the treatment of anxiety
AU1116895A (en) Use of theophylline for the manufacture of a medicament for the treatment of asthma
AU1587495A (en) Process for the treatment of contaminated land
AU6927894A (en) 4-amidinophenylsulphonamides for the treatment of thrombo-embolitic conditions
AU3263795A (en) Medicament for treatment or prophylaxis of incontinence
AU5627796A (en) Medicaments for the treatment or prophylaxis of ischemia-reperfusion injury
HU9502623D0 (en) Use of substituted alkyl-nitrates for the treatment of pathologically increased intraocular pressure
ZA931063B (en) Treatment of glaucoma.
AU5699396A (en) Compositions for the treatment of skin conditions
AU7726796A (en) Use of 3-oxa-d-prostaglandins for the manufacture of a medicament for the treatment of glaucoma
UA29461C2 (uk) Засіб для лікування амілоїдозу, спосіб лікування амілоїдозу
AU3306997A (en) Use of h2-antagonists for the manufacture of a topical composition for the treatment of colds
SI0778025T1 (en) Use of 8,9-dehydroestrone for the manufacture of a medicament for the treatment of diseases caused by free radicals

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AU BB BG BR CA CN CZ EE GE HU IL IS JP KP KR LK LR LT LV MG MK MN MX NO NZ PL RO SG SI SK TR TT UA UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AL AU BB BG BR CA CN CZ EE GE HU IL IS JP KP KR LK LR LT LV MG MK MN MX NO NZ PL RO SG SI SK TR TT UA UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase